Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles B Hicks

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
AIDS Clinical Care|February 18, 2009
Top stories of 2008. Beyond abacavir/3TC: good news on first-line regimensCharles B Hicks
AIDS Clinical Care|May 25, 2006
Report from the 13th retrovirus conference. Integrase inhibitors on the wayCharles B Hicks
Journal Watch. AIDS Clinical Care|July 25, 2015
Updated recommendations on INSTI-based regimens for ART-naive patientsCharles B Hicks
Journal Watch. AIDS Clinical Care|May 13, 2010
Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. GSK572--a "next generation" integrase inhibitor?Charles B Hicks
Journal Watch. AIDS Clinical Care|June 24, 2009
Report from the 16th Conference on Retroviruses and Opportunistic Infections. Timing of ART initiation--still no definitive answersCharles B Hicks
Journal Watch. AIDS Clinical Care|June 24, 2009
Report from the 16th Conference on Retroviruses and Opportunistic Infections. Investigational pharmacologic boostersCharles B Hicks
AIDS Clinical Care|May 7, 2005
Report from the 12th Retrovirus Conference. Acute and recent HIV infectionCharles B Hicks
Journal Watch. AIDS Clinical Care|July 13, 2010
Definitive results: IL-2 does not benefit HIV-infected patients. Interleukin-2 improves CD4-cell recovery in patients on antiretroviral therapy, but that benefit does not translate into lower risks for disease or deathCharles B Hicks
AIDS Clinical Care|May 25, 2006
Report from the 13th retrovirus conference. New data on TMC114 and TMC125Charles B Hicks
AIDS Clinical Care|September 26, 2008
Guideline watch. Antiretroviral drug resistance testing--updated guidelines from the IAS-USACharles B Hicks
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
AIDS Clinical Care|February 18, 2009
Top stories of 2008. Beyond abacavir/3TC: good news on first-line regimensCharles B Hicks
AIDS Clinical Care|May 25, 2006
Report from the 13th retrovirus conference. Integrase inhibitors on the wayCharles B Hicks
Journal Watch. AIDS Clinical Care|July 25, 2015
Updated recommendations on INSTI-based regimens for ART-naive patientsCharles B Hicks
Journal Watch. AIDS Clinical Care|May 13, 2010
Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. GSK572--a "next generation" integrase inhibitor?Charles B Hicks
Journal Watch. AIDS Clinical Care|June 24, 2009
Report from the 16th Conference on Retroviruses and Opportunistic Infections. Timing of ART initiation--still no definitive answersCharles B Hicks
Journal Watch. AIDS Clinical Care|June 24, 2009
Report from the 16th Conference on Retroviruses and Opportunistic Infections. Investigational pharmacologic boostersCharles B Hicks
AIDS Clinical Care|May 7, 2005
Report from the 12th Retrovirus Conference. Acute and recent HIV infectionCharles B Hicks
Journal Watch. AIDS Clinical Care|July 13, 2010
Definitive results: IL-2 does not benefit HIV-infected patients. Interleukin-2 improves CD4-cell recovery in patients on antiretroviral therapy, but that benefit does not translate into lower risks for disease or deathCharles B Hicks
AIDS Clinical Care|May 25, 2006
Report from the 13th retrovirus conference. New data on TMC114 and TMC125Charles B Hicks
AIDS Clinical Care|September 26, 2008
Guideline watch. Antiretroviral drug resistance testing--updated guidelines from the IAS-USACharles B Hicks
Pageof 9